Reconstructed Bone (r-Bone™) 3D Cell Culture Service, Mulitiple Myeloma
Human, bone marrow 3D culture model enabling accurate testing of therapeutic agents against multiple myeloma.
zPREDICTA
zPREDICTA is a pioneer in tumor-specific 3D cell culture services for anticancer drug testing. Its proprietary 3D cell culture models reconstruct the tumor microenvironment by incorporating tissue-specific extracellular matrix (ECM) and disease-specific medium supplements. Such an environment supports long-term (>30 days) culture of primary human cells and maintains heterogeneity of the original specimen.
zPREDICTA’s platform is compatible with any drug class (i.e. small molecules, ADCs, biologics, and cellular therapies), multiple cell and tissue types (including cell lines and primary cells from both solid tumors and hematological malignancies), and a wide variety of readouts. zPREDICTA’s models are being used for efficacy screening of anticancer compounds (including immuno-oncology agents and CAR-T cells), evaluation of mechanisms of drug resistance, rescue of failed drug candidates, assessment of off-target toxicity, and many other applications.
The predictive value of the zPREDICTA platform has been demonstrated in an ongoing clinical study, which has shown a strong correlation between drug efficacy as measured in our platform and actual clinical response. zPREDICTA’s platform offers superior compound attrition management due to its significantly enhanced predictive capabilities compared to 2D models or non-tissue-specific 3D models.
Reconstructed Bone (r-Bone™) 3D Cell Culture Service, Acute Myelogenous Leukemia (AML)
Human, bone marrow 3D culture model enabling accurate testing of therapeutic agents against acute myelogenous leukemia (AML).
Browse Products by Field
zPREDICTA is a pioneer in tumor-specific 3D cell culture services for anticancer drug testing. Its proprietary 3D cell culture models reconstruct the tumor microenvironment by incorporating tissue-specific extracellular matrix (ECM) and disease-specific medium supplements. Such an environment supports long-term (>30 days) culture of primary human cells and maintains heterogeneity of the original specimen.
zPREDICTA’s platform is compatible with any drug class (i.e. small molecules, ADCs, biologics, and cellular therapies), multiple cell and tissue types (including cell lines and primary cells from both solid tumors and hematological malignancies), and a wide variety of readouts. zPREDICTA’s models are being used for efficacy screening of anticancer compounds (including immuno-oncology agents and CAR-T cells), evaluation of mechanisms of drug resistance, rescue of failed drug candidates, assessment of off-target toxicity, and many other applications.
The predictive value of the zPREDICTA platform has been demonstrated in an ongoing clinical study, which has shown a strong correlation between drug efficacy as measured in our platform and actual clinical response. zPREDICTA’s platform offers superior compound attrition management due to its significantly enhanced predictive capabilities compared to 2D models or non-tissue-specific 3D models.